Підписатись
Haji Chalchal
Haji Chalchal
Clinical Associate Proffesor
Підтверджена електронна адреса в saskcancer.ca
Назва
Посилання
Посилання
Рік
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ...
New England Journal of Medicine 359 (17), 1757-1765, 2008
44562008
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27—a randomized controlled phase III trial
PE Goss, JN Ingle, KI Pritchard, MJ Ellis, GW Sledge, GT Budd, ...
Journal of clinical oncology 31 (11), 1398, 2013
2802013
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group
TE Witzig, AM Vukov, TM Habermann, S Geyer, PJ Kurtin, ...
Journal of clinical oncology 23 (6), 1103-1108, 2005
2462005
Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by …
M Burnell, MN Levine, JAW Chapman, V Bramwell, K Gelmon, B Walley, ...
Journal of Clinical Oncology 28 (1), 77, 2010
1732010
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...
Annals of oncology 33 (12), 1250-1268, 2022
1552022
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
JJ Biagi, AM Oza, HI Chalchal, R Grimshaw, SL Ellard, U Lee, H Hirte, ...
Annals of Oncology 22 (2), 335-340, 2011
1532011
Effect of metformin vs placebo on weight and metabolic factors in NCIC CTG MA. 32
PJ Goodwin, WR Parulekar, KA Gelmon, LE Shepherd, JA Ligibel, ...
Journal of the National Cancer Institute 107 (3), djv006, 2015
1462015
Phase II study of PX-866 in recurrent glioblastoma
MW Pitz, EA Eisenhauer, MV MacNeil, B Thiessen, JC Easaw, ...
Neuro-oncology 17 (9), 1270-1274, 2015
1302015
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial
T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ...
JAMA oncology 8 (11), 1571-1578, 2022
972022
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA. 27B): a companion analysis of a randomised controlled trial
PE Goss, DL Hershman, AM Cheung, JN Ingle, S Khosla, V Stearns, ...
The Lancet Oncology 15 (4), 474-482, 2014
622014
A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer …
MJ Burnell, L Shepherd, K Gelmon, V Bramwell, B Walley, E Vandenberg, ...
Cancer Research 72, 2012
512012
A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian Cancer Trials Group Trial
DJ Jonker, PA Tang, H Kennecke, SA Welch, MC Cripps, T Asmis, ...
Clinical Colorectal Cancer 17 (3), 231-239. e7, 2018
492018
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group
MD Seftel, J Kuruvilla, T Kouroukis, V Banerji, G Fraser, M Crump, ...
Leukemia & Lymphoma 58 (6), 1358-1365, 2017
402017
Comparisons of outcomes of real-world patients with advanced pancreatic cancer treated with FOLFIRINOX versus gemcitabine and nab-paclitaxel: a population-based cohort study
N Papneja, A Zaidi, H Chalchal, M Moser, K Tan, C Olson, K Haider, ...
Pancreas 48 (7), 920-926, 2019
362019
Primary tumor location and survival in the general population with metastatic colorectal cancer
S Ahmed, P Pahwa, D Le, H Chalchal, S Chandra-Kanthan, N Iqbal, ...
Clinical Colorectal Cancer 17 (2), e201-e206, 2018
322018
A phase III adjuvant trial of sequenced EC+ filgrastim+ epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node …
MJ Burnell IV, MN Levine, JA Chapman, V Bramwell, T Vandenberg, ...
Journal of Clinical Oncology 25 (18_suppl), 550-550, 2007
272007
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA. 21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer
AE Lohmann, JAW Chapman, MJ Burnell, MN Levine, E Tsvetkova, ...
Breast Cancer Research and Treatment 150, 605-611, 2015
242015
Prognoses of T4 breast cancer subsets
M El-Tamer, S Hussain, J Weedon, H Chalchal, A Chakrabarti, C Sohn, ...
Annals of Surgical Oncology 9, 340-345, 2002
232002
Impaired venous hemodynamics in a minority of patients with chronic leg ulcers due to sickle cell anemia.
H Chalchal, W Rodino, S Hussain, I Haq, T Panetta, W Solomon, P Gillette, ...
VASA. Zeitschrift fur Gefasskrankheiten 30 (4), 277-279, 2001
212001
Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
S Ali, J Hendry, D Le, PK Mondal, A Sami, H Chalchal, K Haider, ...
Scientific Reports 12 (1), 1068, 2022
142022
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20